Cargando…
A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies
B cell malignancies are classified as different types such as B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL) and B cell non-Hodgkin lymphoma (NHL) based on cell surface expression of various clusters of differentiation molecules. CD19 is a B cell lineage-specific ant...
Autores principales: | Liu, Jia, Wang, Luyao, Yang, Hongbo, Xing, Meng, Liu, Shihai, Yu, Zhuang, Ma, Leina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799169/ https://www.ncbi.nlm.nih.gov/pubmed/35117929 http://dx.doi.org/10.21037/tcr-20-1044 |
Ejemplares similares
-
Engineering better chimeric antigen receptor T cells
por: Zhang, Hao, et al.
Publicado: (2020) -
Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
por: Ying, Zhitao, et al.
Publicado: (2021) -
Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019) -
Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016) -
Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
por: Yan, Weiqi, et al.
Publicado: (2020)